Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS

Dianthus Therapeutics (NASDAQ:DNTH) posted its quarterly earnings results on Tuesday. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.25, FiscalAI reports. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock traded up $0.90 during trading on Tuesday, reaching $90.24. The stock had a trading volume of 343,810 shares, compared to its average volume of 552,587. The stock has a fifty day moving average price of $79.60 and a two-hundred day moving average price of $55.57. Dianthus Therapeutics has a 52 week low of $16.64 and a 52 week high of $96.50.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on DNTH shares. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Monday, April 20th. Oppenheimer boosted their price objective on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a report on Monday, March 9th. Jefferies Financial Group set a $98.00 price objective on shares of Dianthus Therapeutics and gave the company a “buy” rating in a report on Monday, March 9th. Wolfe Research started coverage on shares of Dianthus Therapeutics in a report on Thursday, April 9th. They set an “outperform” rating and a $98.00 price objective for the company. Finally, Stifel Nicolaus set a $120.00 price objective on shares of Dianthus Therapeutics in a report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $115.55.

Insider Transactions at Dianthus Therapeutics

In related news, CAO Edward Carr sold 43,682 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $3,559,646.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marino Garcia sold 122,918 shares of the stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $10,016,587.82. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 323,021 shares of company stock valued at $26,564,008. 3.02% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in DNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after purchasing an additional 618 shares during the last quarter. American Century Companies Inc. lifted its stake in Dianthus Therapeutics by 13.2% in the second quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after acquiring an additional 6,323 shares during the last quarter. Invesco Ltd. lifted its stake in Dianthus Therapeutics by 31.1% in the second quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock valued at $390,000 after acquiring an additional 4,962 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Dianthus Therapeutics by 14.5% in the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock valued at $21,887,000 after acquiring an additional 149,200 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Dianthus Therapeutics in the second quarter valued at $27,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.